ArticleJournal of materials science. Materials in medicine2026
Cholesterol-depleting nanozyme amplifies membrane-diffusive ferroptosis for potentiating anti-tumor immunity in colorectal cancer.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To overcome limitations of conventional therapies and low immunotherapy response in colorectal cancer, we developed a cholesterol-depleting nanozyme (ChOx@Fe@C-MOF). This platform synergistically induces ferroptosis and anti-tumor immunity by integrating cholesterol oxidase (ChOx) with a carbonized MIL-100(Fe) carrier (Fe@C-MOF). ChOx disrupts tumor membrane lipid rafts to downregulate GPX4 and generate H₂O₂, while Fe@C-MOF catalyzes ROS production and glutathione depletion. In vitro, ChOx@Fe@C-MOF triggered robust lipid peroxidation, immunogenic cell death, and tumor growth suppression in CT26 models. It enhanced dendritic cell maturation, CD8⁺ T-cell infiltration, and cytokine production, converting immunosuppressive "cold" tumors into immunologically "hot" microenvironments. This strategy integrates cholesterol metabolism intervention with nanozyme catalysis for synergistic ferroptosis-immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.